Lyophilization Method for Controlled Nucleation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lyophilization processes face challenges in controlling the random nucleation process during freezing, leading to vial-to-vial variations in ice crystal structure and prolonged drying times, which affects the uniformity and efficiency of the freeze-drying process.
Innovation Solution
A method involving cooling a material to a temperature below its phase transition temperature followed by rapid depressurization to induce nucleation, allowing for controlled nucleation across multiple vials simultaneously within a narrow temperature range.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If natural stochastic nucleation is used during freezing, then the process is simple to operate, but the nucleation temperature varies randomly across vials causing vial-to-vial variation in ice crystal structure and prolonged drying times
Solution Approach 1:
The patent applies preliminary action by pre-cooling the chamber to a temperature below the freezing point of the solution before introducing the vapor suspension of ice particles. This ensures that when nucleation is triggered, the entire chamber is already at the optimal temperature for controlled simultaneous nucleation across all vials, eliminating the random temperature variations that occur with natural stochastic nucleation.
Solution Approach 2:
The patent uses an intermediary substance (vapor suspension of ice particles or other nucleating agents) to mediate the nucleation process. This intermediary is introduced into the chamber and facilitates controlled nucleation by providing nucleation sites that trigger freezing at a uniform temperature across all vials, replacing the uncontrolled random nucleation process.
2Temperature
If additives are used to increase nucleation temperature, then the average nucleation temperature increases, but the composition of the medium is changed which is not acceptable for FDA regulated pharmaceutical products
Solution Approach 1:
The patent introduces an intermediary nucleating agent (vapor suspension of ice particles or other substances) into the chamber that temporarily facilitates nucleation without becoming part of the final product composition. The intermediary triggers controlled nucleation at elevated temperatures but is removed or does not contaminate the pharmaceutical solution, thus maintaining composition stability while achieving higher nucleation temperatures.
Solution Approach 2:
The patent creates an inert environment by using a vapor suspension that provides nucleation sites without chemically interacting with or contaminating the pharmaceutical solution. The nucleating vapor acts as a temporary facilitator that enables controlled nucleation while maintaining the purity and compositional integrity of the pharmaceutical product.
3Temperature
If the ice fog method is used to induce nucleation, then nucleation can be initiated, but the nucleation event does not occur concurrently in all vials creating temperature differences and increased non-uniformity
Solution Approach 1:
The patent applies preliminary action by pre-cooling the entire chamber to a uniform temperature below the freezing point before introducing the nucleating vapor suspension. This ensures that all vials are at the same temperature and ready for simultaneous nucleation when the vapor is introduced, eliminating the sequential nucleation that occurs when vials are at different temperatures.
Solution Approach 2:
The patent creates equipotential conditions by maintaining a uniform temperature throughout the chamber before nucleation. All vials are held at the same sub-freezing temperature, ensuring that when the nucleating vapor suspension is introduced, nucleation occurs simultaneously and uniformly across all vials, eliminating temperature differences that cause non-uniformity.
4Manufacturing precision
If the drying stage is extended to accommodate the range of ice crystal sizes, then product uniformity is improved, but the processing time is excessively long
Solution Approach 1:
The patent applies preliminary action by controlling the nucleation temperature to be uniformly elevated across all vials before drying begins. By ensuring that all vials nucleate at the same higher temperature, the ice crystal size and structure are uniformly controlled in advance, which allows the drying stage to be shorter while still achieving uniform product quality across all vials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a more uniform lyophilized product with reduced processing time by ensuring consistent nucleation temperatures and ice crystal structures, thereby accelerating the freeze-drying process.
Implementation Method 1
The aqueous solution in each vial is cooled below the thermodynamic freezing temperature of the solution and remains in a sub-cooled metastable liquid state until nucleation occurs.
Implementation Method 2
the material is initially cooled to a temperature below a phase transition temperature and subsequently depressurized so as to induce nucleation of freezing in the material
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Method for lyophilization or freeze-drying is provided. During the freezing step, the material or solution to be frozen is initially brought to a temperature near or below its freezing temperature after which the pressure in the freeze-dryer chamber is reduced to induce nucleation of the material.